FIG. 1





FIG. 3

PVPPGEDSKDVAAPHRQPLTSSER
IDKQIRYILDGISARKETCNKSNM
CESSKEALAENNLNLPKMAEKDGC
FQSGFNEETCLVKIITGLLEFEVY
LEYLQNRFESSEEQARAVQMSTKV
LIQFQKKAKNLDAITTPDPTTNAS
LLTKLQAQNQWLQDMTTHLILRSF
KEFLQSSLRALRQM

FIG. 4

MLAVGCALLAALLAAPGAALAPRRCPAQEVARGVLTSLPGDSVT
LCTPGVEPENDATVHWVLRKPAAGSHPSRWAGMGRRLLLRSVQL
HDSGNYSCYRAGRPAGTVHLLVDVPPEEPQLSCFRKSPLSNVVC
EWGPRSTPSLTTKAVLLVRKFQNSPAEDFQEPCQYSQESQKFSC
QLAVPEGDSSFYIVSMCVASSVGSKFSKTQTFQGCGILQPDPPA
NITVTAVARNPRWLSVTWQDPHSWNSSFYRLRFELRYRAERSKT
FTTWMVKDLQHHCVIHDAWSGLRHVVQLRAQEEFGQGEWSEWSP
EAMGTPWTESRSPPAENEVSTPMQALTTNKDDDNILFRDSANAT
SLPSRRRGSCGL

FIG. 2



10 MAY 2004

FIG. 5



3/14
10 MAY 2004



CCL2/MCP-1
CCL11/Eotaxin
CXCL10/IP-10
CCL3/MIP-1
CCL4/MIP-1
CCL5/RANTES
Chemokine (pg/ml)
sIL-6R isoform (Log ng/ml)
0 1 10 100

FIG. 6

FIG. 7



A
CCL2/MCP-1
CC-chemokine (pg/ml)
12000
8000
4000
0
mAb (μg/ml)
0
1
10
CCL5/RANTES
1500
1000
500
0
mAb (μg/ml)
0
1
10
B
CCL5/RANTES
CCL5/RANTES (pg/ml)
900
600
300
0
PC-sIL-6R (ng/ml)
0
1
10
100

FIG. 8



CCL5
CCL2
12000
11500
1000
500
0
14000
10500
7000
3500
0
1
10
100
Chemokine (pg/ml)
Time (Log hrs)

FIG. 9



RANTES-1.4
ΔNF-κB
ΔSTAT
ΔNF-IL-6
0 5 10 15 20
DS+IL-6
PC+IL-6
IL-6
IL-1
Control

FIG. 10



NF-κB
SIE (m67)
cEBP
Control
IL-1β
PC +IL-6
DS+IL-6
Control
IL-1β
PC +IL-6
DS+IL-6
Control
IL-1β
PC +IL-6
DS+IL-6

FIG. 11



A
IL-6
sIL-6R
Mediator (pg/ml)
4500
3000
1500
0
3000
2000
1000
0
B
CCL5
CCL2
CXCL10
CXCL8
Chemokine (pg/ml)
450
300
150
0
4500
3000
1500
0
60
40
20
0
300
200
100
0
Mock
HYPER-DS-sIL-6R

FIG. 12



A
IL-6 -/-
Neutrophils (x10^4 cells/ml)
75
50
25
0
Control
PC-sIL-6R
DS-sIL-6R
SES
SES+PC-sIL-6R
SES+DS-sIL-6R
*
*
*
B
IL-6 -/-
CCL5/RANTES (pg/ml)
90
60
30
0
Control
PC-sIL-6R
DS-sIL-6R
SES
SES+PC-sIL-6R
SES+DS-sIL-6R
**
**

FIG. 13



A
CCL5
CXCL10
CCL5 (pg/ml)
CXCL10 (pg/ml)
150
100
50
0
450
300
150
0
0 3 6 9 12
Time (hours)
B
CCL5
CXCL10
CCL5 (pg/ml)
CXCL10 (pg/ml)
150
100
50
0
450
300
150
0
0 3 6 9 12
Time (hours)

FIG. 14



IL-6+/+
-/-
Control
SES
29.05±3.35
27.0±3.4
39.5±3.4
26.5±5.4
FL2-H
FL1-H
CC R5
CXCR3

Fig. 15A





IL-6-/-
DS-sIL-6R/IL-6
40.78±6.05
SES + DS-sIL-6R/IL-6
35.8±3.98
SES + DS-sIL-6R/IL-6+ sgp130
25.98±1.76
FL2-H
FL1-H
10^0
10^1
10^2
10^3
10^4
CC
R5
CXCR3

FIG. 15B


60
30
0
% CCR5+/ CD3+ cells
**
*
SES
DS/SES
Control
DS/IL-6
DS/SES/sgp130


12
6
0
Total leukocytes (x10^5/cells/ml)
**
**
**
**
SES
DS/SES
Control
DS/IL-6
DS/SES/sgp130